Heat and immune boost: new combo tackles Hard-to-Treat cancers

NCT ID NCT03993678

Completed Disease control Sponsor: Swiss Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial tested a two-step treatment for people with advanced solid tumors that no longer respond to standard therapies. First, a laser heats and destroys part of the tumor. Then, a drug called IP-001 is injected directly into the treated area to help the immune system recognize and attack remaining cancer cells throughout the body. The study enrolled 28 adults with various cancers, including melanoma and soft tissue sarcoma, to check safety and early signs of effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

melanoma neoplasm sarcoma soft tissue sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS

Contacts and locations

Locations

Inselspital, Bern

Bern, CH-3010, Switzerland
Kantonsspital Graubünden

Chur, 7000, Switzerland
Kantonsspital St. Gallen

Sankt Gallen, CH-9007, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.